Long-term damage to the ENT system in Wegener’s granulomatosis

被引:0
作者
Marcos Martinez Del Pero
Michael Walsh
Raashid Luqmani
Oliver Flossmann
Chetan Mukhtyar
Piyush Jani
Niels Rasmussen
David Jayne
机构
[1] Addenbrooke’s Hospital,Department of Otolaryngology
[2] Cambridge University Hospitals,Department of Medicine
[3] Addenbrooke’s Hospital,Departments of Medicine and Clinical Epidemiology and Biostatistics
[4] Cambridge University Hospitals,Department of Rheumatology
[5] McMaster University,Department of Nephrology
[6] Nuffield Orthopaedic Centre,Department of Rheumatology
[7] University of Oxford,Department of Otolaryngology
[8] Royal Berkshire Hospital,ENT Department, Box 48
[9] Norfolk and Norwich University Hospital,undefined
[10] Rigshospitalet,undefined
[11] Addenbrooke’s Hospital,undefined
来源
European Archives of Oto-Rhino-Laryngology | 2011年 / 268卷
关键词
Wegener’s granulomatosis; ANCA-associated vasculitis; Ear; Nose and throat; Otolaryngology; Damage;
D O I
暂无
中图分类号
学科分类号
摘要
The objectives of the study are to describe long-term ENT damage and assess risk factors in patients with newly diagnosed and treated Wegener’s granulomatosis (WG) using the vasculitis damage index (VDI). Data from four randomised controlled trials carried out by the European Vasculitis Study Group was used. Patients newly diagnosed with WG with complete data at 5 years were included. Patients enrolled into the trials without 5-year data were excluded. Total and ENT VDI scores were recorded at 12 months and after at least 5 years. Logistic regression models were constructed to assess risk factors using total ENT and overall VDI score over the follow-up period, the proportion of patients with increased VDI score and the presence or absence of damage as the main outcomes. One hundred and thirty-eight patients were included. Ninety patients (65%) had long-term damage and 81% of these (73/90) developed some damage in the first 12 months. Positive ENT activity score (BVAS) at baseline and relapses were associated with higher ENT VDI scores long-term (OR = 6.90, 95% CI 2.01–23.75; OR = 2.65, 95% CI 1.20–5.82). Increasing BVAS score showed a trend towards lower VDI scores (OR = 0.93, 95% CI 0.88–0.99). Only ENT relapses and number of relapses were associated with an increase in VDI over time (OR = 8.38, 95% CI 3.10–22.68; OR = 1.79, 95% CI 1.24–2.58). In conclusion, most of the ENT damage in these patients was accrued within 12 months of diagnosis. We have shown an association between later ENT damage and the presence of ENT disease at baseline; lower initial BVAS and higher rate of disease relapse.
引用
收藏
页码:733 / 739
页数:6
相关论文
共 130 条
[21]  
Walsh M(2005)Damage caused by Wegener’s granulomatosis and its treatment: prospective data from the Wegener’s Granulomatosis Etanercept Trial (WGET) Arthritis Rheum 52 2168-770
[22]  
Herlyn K(2008)Novel therapies for anti-neutrophil cytoplasmic antibody-associated vasculitis Drugs 68 747-268
[23]  
Seo P(2005)Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody-associated vasculitis Arthritis Rheum 52 262-335
[24]  
Hellmich B(2009)B-cell depletion with rituximab for refractory head and neck Wegener’s granulomatosis: a cohort study Clin Otolaryngol 34 328-761
[25]  
Reimer J(2009)Sinonasal Wegener granulomatosis: a single-institution experience with 120 cases Laryngoscope 119 757-837
[26]  
Merkel PA(2004)Hearing loss in Wegener’s granulomatosis Otol Neurotol 25 833-undefined
[27]  
Exley AR(undefined)undefined undefined undefined undefined-undefined
[28]  
Bacon PA(undefined)undefined undefined undefined undefined-undefined
[29]  
Luqmani RA(undefined)undefined undefined undefined undefined-undefined
[30]  
Kitas GD(undefined)undefined undefined undefined undefined-undefined